These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 9591584)
1. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. M'Kacher R; Schlumberger M; Légal JD; Violot D; Béron-Gaillard N; Gaussen A; Parmentier C J Nucl Med; 1998 May; 39(5):825-9. PubMed ID: 9591584 [TBL] [Abstract][Full Text] [Related]
2. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193 [TBL] [Abstract][Full Text] [Related]
3. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. M'Kacher R; Légal JD; Schlumberger M; Aubert B; Beron-Gaillard N; Gaussen A; Parmentier C J Nucl Med; 1997 Mar; 38(3):377-80. PubMed ID: 9074522 [TBL] [Abstract][Full Text] [Related]
4. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288 [TBL] [Abstract][Full Text] [Related]
5. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine]. Katz N; Esik O; Füzy M; Gundy S Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113 [TBL] [Abstract][Full Text] [Related]
6. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer. Hernández-Jardines A; Molina B; del Castillo V; Papadakis M; Rivera T; Azorín J; Herrera LA; Yokoyama E; Frías S Rev Invest Clin; 2010; 62(1):31-8. PubMed ID: 20415057 [TBL] [Abstract][Full Text] [Related]
7. Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. Serna A; Alcaraz M; Navarro JL; Acevedo C; Vicente V; Canteras M Radiat Prot Dosimetry; 2008; 129(4):372-80. PubMed ID: 17951242 [TBL] [Abstract][Full Text] [Related]
8. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257 [TBL] [Abstract][Full Text] [Related]
9. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684 [TBL] [Abstract][Full Text] [Related]
10. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014 [TBL] [Abstract][Full Text] [Related]
11. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. Baugnet-Mahieu L; Lemaire M; Léonard ED; Léonard A; Gerber GB Radiat Res; 1994 Dec; 140(3):429-31. PubMed ID: 7972697 [TBL] [Abstract][Full Text] [Related]
12. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099 [TBL] [Abstract][Full Text] [Related]
13. Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer. Khvostunov IK; Saenko VA; Krylov V; Rodichev A; Yamashita S Radiat Environ Biophys; 2017 Aug; 56(3):213-226. PubMed ID: 28526978 [TBL] [Abstract][Full Text] [Related]
14. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer. Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198 [TBL] [Abstract][Full Text] [Related]
16. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Chiesa C; Castellani MR; Vellani C; Orunesu E; Negri A; Azzeroni R; Botta F; Maccauro M; Aliberti G; Seregni E; Lassmann M; Bombardieri E Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):546-61. PubMed ID: 19910908 [TBL] [Abstract][Full Text] [Related]
17. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy). Bianchi L; Baroli A; Lomuscio G; Pedrazzini L; Pepe A; Pozzi L; Chiesa C Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):515-21. PubMed ID: 23358404 [TBL] [Abstract][Full Text] [Related]
18. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe? de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231 [TBL] [Abstract][Full Text] [Related]
19. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer. Lassmann M; Luster M; Hänscheid H; Reiners C J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368 [No Abstract] [Full Text] [Related]
20. 131I ablation treatment in young females after the Chernobyl accident. Travis CC; Stabin MG J Nucl Med; 2006 Oct; 47(10):1723-7. PubMed ID: 17015910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]